Klin Farmakol Farm. 2012;26(3):135-138
Rivaroxaban
- Ústav farmakologie LF UP a FN Olomouc
Rivaroxaban is an oral selective, direct factor Xa inhibitor. It has well predictable pharmacodynamics and pharmacokinetics. After oral
administration is well absorbed, bioavailability varies between 80 and 100 %. It is from 92 to 95 % bound to plasma proteins, an average
volume of distribution is 50 liters. The main metabolizing systems are cytochromes P450 3A4 and 2J2. It is excreted mainly via kidneys,
about one third of the administered activity being excreted unchanged, primarily by tubular secretion. The remaining two thirds are
excreted as inactive metabolites via the urine and bile. Mean terminal half-life in younger individuals is 5 to 9 hours, and 11–13 hours
in older individuals. Rivaroxaban pharmacokinetics is minimally affected by age or sex of the patient, and even extremely low or high
weight does not cause the need of the dose adjustment, as well as mild-to- moderate renal or hepatic insufficiency.
Keywords: rivaroxaban, anticoagulants, pharmacokinetics
Published: November 1, 2012 Show citation
References
- Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008; 17: 925-937.
Go to original source... 
Go to PubMed... - Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010; 30(3): 376-381. Go to original source... Go to PubMed...
- Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008; 65(16): 1520-1529. Go to original source... Go to PubMed...
- Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78(4): 412-421. Go to original source... Go to PubMed...
- Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61(12): 873-880. Go to original source... Go to PubMed...
- Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos. 2009; 37: 1056-1064. Go to original source... Go to PubMed...
- Kubitza D Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral direct Factor Xa inhibitor. Blood 2006; 108(11): 905. Go to original source...
- Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007; 47(2): 218-226. Go to original source... Go to PubMed...
- Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010; 70(5): 703-712. Go to original source... Go to PubMed...
- Halabi A, Kubitza D, Zuehlsdorf M, et al. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. Abstract P-M-635. Poster presentation at the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 6-12 July 2007.
- Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116(2): 180-187. Go to original source... Go to PubMed...
- Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-ranging study. Blood 2008; 112(6): 2242-2247. Go to original source... Go to PubMed...
- Mueck W, Lensing AWA, Agnelli G, Decousus G, Prandoni P, Misselwitz F, Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention. Clin Pharmacokinet 2011; 50(10): 675-686. Go to original source... Go to PubMed...
- Coleman CI, Roberts MS, Sobieraj DM, Lee S, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherenceCurr Med Res Opin 2012; 28: 1-12. Go to original source... Go to PubMed...
- Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011; 338(1): 372-380. Go to original source... Go to PubMed...
- Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012; 46(9): 1232-1238. Go to original source... Go to PubMed...
- Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-990. Go to original source... Go to PubMed...